BillionToOne, Inc. (BLLN): Cost of Revenue
$96.65M
Year ended 2025-12-31
$114.19M
Trailing 12 months to 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $96.65M | +34.9% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $71.67M | +31.7% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $54.42M | n/a | 2026-03-11, From 2023-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $96.65M | +34.9% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $191.80M | +8.8% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $71.03M | +18.0% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $349.01M | +20.4% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $53.87M | -6.8% |
| Exagen Inc. (XGN) | 2025-12-31 | $27.78M | +23.3% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $23.02M | +20.2% |
| Quest Diagnostics Inc (DGX) | 2025-12-31 | $7.37B | +11.2% |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $6.34M | -22.9% |
Compare BLLN, FLGT, CSTL, GH side by side · Screen every company in Services-Medical Laboratories ↗